Photo taken from primewomen.com
Jun 29, 2024, 13:50
Chemotherapy with adjuvant nivolumab versus placebo for GEJ cancer
Syed A. Ahmad, Chief of Surgical Oncology at The University of Cincinnati, made the following post on X:
“Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5) .”
Additional information.
Source: Syed A. Ahmad/X
cancer
chemotherapy
gastric cancer
gastro-oesophageal junction cancer
Hyun Cheol Chung
Jen-Shi Chen
Jiafu Ji
Jong Gwang Kim
Keun Won Ryu
Li-Tzong Chen
Li-Yuan Bai
lymph-node dissection
Masanori Terashima
Min-Hee Ryu
Mitsuru Sasako
Narikazu Boku
nivolumab
Norimasa Fukushima
OncoDaily
Oncology
Shinichi Sakuramoto
Shunsuke Hagihara
Sun Young Rha
Syed A. Ahmad
Ta-Sen Yeh
Tae Yong Kim
Takanobu Yamada
Takashi Nakada
Takeshi Omori
The University of Cincinnati
Yasunori Nishida
Yoon-Koo Kang
Yoshinori Hirashima
Young Woo Kim
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023